-
1
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
-
(2002)
Nature
, vol.417
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
-
2
-
-
38949131824
-
BRAF(E600) in benign and Malignant human tumours
-
Michaloglou C, Vredeveld LC, Mooi W.J., et al: BRAF(E600) in benign and malignant human tumours. Oncogene 27:877-895, 2008
-
(2008)
Oncogene
, vol.27
, pp. 877-895
-
-
Michaloglou, C.1
Vredeveld, L.C.2
Mooi, W.J.3
-
3
-
-
0030771387
-
Ras effectors and their role in mitogenesis and oncogenesis
-
Joneson T, Bar-Sagi D: Ras effectors and their role in mitogenesis and oncogenesis. J Mol Med (Berl) 75:587-593, 1997
-
(1997)
J Mol Med (Berl)
, vol.75
, pp. 587-593
-
-
Joneson, T.1
Bar-Sagi, D.2
-
4
-
-
84922949171
-
Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes
-
Sinicrope FA, Shi Q, Smyrk T.C., et al: Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 148:88-99, 2015
-
(2015)
Gastroenterology
, vol.148
, pp. 88-99
-
-
Sinicrope, F.A.1
Shi, Q.2
Smyrk, T.C.3
-
5
-
-
84881640407
-
Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication
-
Lochhead P, Kuchiba A, Imamura Y., et al: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 105:1151-1156, 2013
-
(2013)
J Natl Cancer Inst
, vol.105
, pp. 1151-1156
-
-
Lochhead, P.1
Kuchiba, A.2
Imamura, Y.3
-
6
-
-
79958817037
-
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
-
Tran B, Kopetz S, Tie J., et al: Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117:4623-4632, 2011
-
(2011)
Cancer
, vol.117
, pp. 4623-4632
-
-
Tran, B.1
Kopetz, S.2
Tie, J.3
-
7
-
-
77956030786
-
Inhibition of mutated, activated BRAF in metastatic melanoma
-
Flaherty KT, Puzanov I, Kim K.B., et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
-
(2010)
N Engl J Med
, vol.363
, pp. 809-819
-
-
Flaherty, K.T.1
Puzanov, I.2
Kim, K.B.3
-
8
-
-
84863012433
-
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer
-
Yang H, Higgins B, Kolinsky K., et al: Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 72:779-789, 2012
-
(2012)
Cancer Res
, vol.72
, pp. 779-789
-
-
Yang, H.1
Higgins, B.2
Kolinsky, K.3
-
9
-
-
84880211812
-
Implementation of timeline reforms speeds initiation of national cancer institute-sponsored trials
-
Abrams JS, Mooney MM, Zwiebel J.A., et al: Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst 105:954-959, 2013
-
(2013)
J Natl Cancer Inst
, vol.105
, pp. 954-959
-
-
Abrams, J.S.1
Mooney, M.M.2
Zwiebel, J.A.3
-
10
-
-
84864222696
-
No evidence for interference of H & E staining in DNA testing: Usefulness of DNA extraction from H & E-stained archival tissue sections
-
Morikawa T, Shima K, Kuchiba A., et al: No evidence for interference of H & E staining in DNA testing: Usefulness of DNA extraction from H & E-stained archival tissue sections. Am J Clin Pathol 138:122-129, 2012
-
(2012)
Am J Clin Pathol
, vol.138
, pp. 122-129
-
-
Morikawa, T.1
Shima, K.2
Kuchiba, A.3
-
11
-
-
61449259809
-
Epidermal growth factor receptor Abnormalities in the pathogenesis and progression of lung adenocar-cinomas
-
Tang X, Varella-Garcia M, Xavier A.C., et al: Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocar-cinomas. Cancer Prev Res (Phila) 1:192-200, 2008
-
(2008)
Cancer Prev Res (Phila)
, vol.1
, pp. 192-200
-
-
Tang, X.1
Varella-Garcia, M.2
Xavier, A.C.3
-
12
-
-
84887832513
-
The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarci-noma after pancreaticoduodenectomy
-
Shroff S, Overman MJ, Rashid A, et al: The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarci-noma after pancreaticoduodenectomy. Arch Pathol Lab Med 137:1619-1626, 2013
-
(2013)
Arch Pathol Lab Med
, vol.137
, pp. 1619-1626
-
-
Shroff, S.1
Overman, M.J.2
Rashid, A.3
-
13
-
-
79955397102
-
DNA methylation predicts recurrence from resected stage III proximal colon cancer
-
Ahn JB, Chung WB, Maeda O, et al: DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer 117:1847-1854, 2011
-
(2011)
Cancer
, vol.117
, pp. 1847-1854
-
-
Ahn, J.B.1
Chung, W.B.2
Maeda, O.3
-
14
-
-
0038678777
-
Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites
-
Colella S, Shen L, Baggerly K.A., et al: Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques 35:146-150, 2003
-
(2003)
Biotechniques
, vol.35
, pp. 146-150
-
-
Colella, S.1
Shen, L.2
Baggerly, K.A.3
-
15
-
-
0042307371
-
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations
-
Dressman D, Yan H, Traverso G., et al: Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A 100: 8817-8822, 2003
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, pp. 8817-8822
-
-
Dressman, D.1
Yan, H.2
Traverso, G.3
-
16
-
-
84908219463
-
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer
-
Morris V, Overman MJ, Jiang Z.Q., et al: Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 13:164-171, 2014
-
(2014)
Clin Colorectal Cancer
, vol.13
, pp. 164-171
-
-
Morris, V.1
Overman, M.J.2
Jiang, Z.Q.3
-
17
-
-
84873360893
-
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents
-
Mao M, Tian F, Mariadason J.M., et al: Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 19:657-667, 2013
-
(2013)
Clin Cancer Res
, vol.19
, pp. 657-667
-
-
Mao, M.1
Tian, F.2
Mariadason, J.M.3
-
18
-
-
36749025213
-
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer
-
Shen L, Toyota M, Kondo Y., et al: Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 104:18654-18659, 2007
-
(2007)
Proc Natl Acad Sci U S A
, vol.104
, pp. 18654-18659
-
-
Shen, L.1
Toyota, M.2
Kondo, Y.3
-
19
-
-
20244383984
-
BRAF mutations in aberrant crypt foci and hyperplastic polyposis
-
Beach R, Chan AO, Wu T.T., et al: BRAF mutations in aberrant crypt foci and hyperplastic polyposis. Am J Pathol 166:1069-1075, 2005
-
(2005)
Am J Pathol
, vol.166
, pp. 1069-1075
-
-
Beach, R.1
Chan, A.O.2
Wu, T.T.3
-
20
-
-
84878066430
-
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer
-
Coffee EM, Faber AC, Roper J, et al: Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer. Clin Cancer Res 19:2688-2698, 2013
-
(2013)
Clin Cancer Res
, vol.19
, pp. 2688-2698
-
-
Coffee, E.M.1
Faber, A.C.2
Roper, J.3
-
21
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
Chapman PB, Hauschild A, Robert C., et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
-
22
-
-
84861083983
-
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial
-
Falchook GS, Long GV, Kurzrock R, et al: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 379:1893-1901, 2012
-
(2012)
Lancet
, vol.379
, pp. 1893-1901
-
-
Falchook, G.S.1
Long, G.V.2
Kurzrock, R.3
-
23
-
-
84861863158
-
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib
-
Corcoran RB, Ebi H, Turke A.B., et al: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2:227-235, 2012
-
(2012)
Cancer Discov
, vol.2
, pp. 227-235
-
-
Corcoran, R.B.1
Ebi, H.2
Turke, A.B.3
-
24
-
-
84863230465
-
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
-
Prahallad A, Sun C, Huang S., et al: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483 100-103, 2012
-
(2012)
Nature
, vol.483
, pp. 100-103
-
-
Prahallad, A.1
Sun, C.2
Huang, S.3
-
25
-
-
77956513286
-
Clinica efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
-
Bollag G, Hirth P, Tsai J., et al: Clinica efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467 596-599, 2010
-
(2010)
Nature
, vol.467
, pp. 596-599
-
-
Bollag, G.1
Hirth, P.2
Tsai, J.3
-
26
-
-
84927604543
-
Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients
-
Yaeger R, Cercek A, O'Reilly EM, et al: Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients Clin Cancer Res 21:1313-1320, 2015
-
(2015)
Clin Cancer Res
, vol.21
, pp. 1313-1320
-
-
Yaeger, R.1
Cercek, A.2
O'Reilly, E.M.3
-
27
-
-
84919393400
-
Phase study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer
-
Van Geel R., Elez E, Bendell J.C., et al: Phase study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer. J Clin Oncol 32, 2014 (suppl; abstr 3514)
-
(2014)
J Clin Oncol
, vol.32
-
-
Van Geel, R.1
Elez, E.2
Bendell, J.C.3
-
28
-
-
0037194728
-
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status
-
Rajagopalan H, Bardelli A, Lengauer C., et al Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418:934, 2002
-
(2002)
Nature
, vol.418
, pp. 934
-
-
Rajagopalan, H.1
Bardelli, A.2
Lengauer, C.3
-
29
-
-
79952463028
-
Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF(V600E) mutation
-
Tie J, Gibbs P, Lipton L., et al: Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 128:2075-2084, 2011
-
(2011)
Int J Cancer
, vol.128
, pp. 2075-2084
-
-
Tie, J.1
Gibbs, P.2
Lipton, L.3
-
30
-
-
1342299898
-
Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas
-
Fransen K, Klintenas M, Osterstrom A., et al: Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25:527-533, 2004
-
(2004)
Carcinogenesis
, vol.25
, pp. 527-533
-
-
Fransen, K.1
Klintenas, M.2
Osterstrom, A.3
-
31
-
-
78650303507
-
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
-
Nazarian R, Shi H, Wang Q., et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-977, 2010
-
(2010)
Nature
, vol.468
, pp. 973-977
-
-
Nazarian, R.1
Shi, H.2
Wang, Q.3
-
32
-
-
84933040790
-
Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations
-
Ahronian LG, Sennott EM, Van Allen EM, et al: Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov 5:358-367, 2015
-
(2015)
Cancer Discov
, vol.5
, pp. 358-367
-
-
Ahronian, L.G.1
Sennott, E.M.2
Van Allen, E.M.3
-
33
-
-
84920598146
-
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer: M.D. Anderson cancer center off label experience
-
Dadu R, Shah K, Busaidy N.L., et al: Efficacy and tolerability of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab 100:E77-E81, 2015
-
(2015)
J Clin Endocrinol Metab
, vol.100
, pp. E77-E81
-
-
Dadu, R.1
Shah, K.2
Busaidy, N.L.3
-
34
-
-
84883879311
-
Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma
-
Peters S, Michielin O, Zimmermann S: Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol 31:e341-e344, 2013
-
(2013)
J Clin Oncol
, vol.31
, pp. e341-e344
-
-
Peters, S.1
Michielin, O.2
Zimmermann, S.3
|